S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Modern Day Options Trading For Beginners! (Ad)pixel
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Modern Day Options Trading For Beginners! (Ad)pixel
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Modern Day Options Trading For Beginners! (Ad)pixel
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Biden's pick to lead FAA withdraws amid shaky Senate support
Modern Day Options Trading For Beginners! (Ad)pixel
Berlin climate proposal fails to get enough yes votes to win
Adele extends Las Vegas residency, plans concert film
NASDAQ:CLDX

Celldex Therapeutics - CLDX Stock Forecast, Price & News

$36.56
+1.46 (+4.16%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$33.83
$36.87
50-Day Range
$35.10
$46.94
52-Week Range
$19.85
$48.40
Volume
861,943 shs
Average Volume
692,944 shs
Market Capitalization
$1.73 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.67

Celldex Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.3% Upside
$66.67 Price Target
Short Interest
Bearish
7.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Celldex Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.58) to ($2.85) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

899th out of 1,005 stocks

Diagnostic Substances Industry

12th out of 15 stocks


CLDX stock logo

About Celldex Therapeutics (NASDAQ:CLDX) Stock

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Stock News Headlines

LifeSci Capital Reaffirms Their Buy Rating on Celldex (CLDX)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
H.C. Wainwright Keeps Their Buy Rating on Celldex (CLDX)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
CLDX.A
As Celldex Recovers, Here's My Strategy
CLDX.A - | Stock Price & Latest News | Reuters
SVB Securities Keeps Their Buy Rating on Celldex (CLDX)
See More Headlines
Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Company Calendar

Last Earnings
11/09/2021
Today
3/26/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CLDX
CUSIP
15117B10
Employees
132
Year Founded
1983

Price Target and Rating

Average Stock Price Forecast
$66.67
High Stock Price Forecast
$73.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
+82.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-112,320,000.00
Net Margins
-4,765.59%
Pretax Margin
-4,765.59%

Debt

Sales & Book Value

Annual Sales
$2.36 million
Book Value
$6.93 per share

Miscellaneous

Free Float
45,932,000
Market Cap
$1.73 billion
Optionable
Optionable
Beta
2.17

Social Links


Key Executives

  • Anthony S. Marucci
    President, Chief Executive Officer & Director
  • Sam Martin
    CFO, Secretary, Treasurer & Senior Vice President
  • Tibor Keler
    Chief Scientific Officer & Executive VP
  • Diane C. YoungDiane C. Young
    Chief Medical Officer & Senior Vice President
  • Elizabeth CrowleyElizabeth Crowley
    Chief Product Development Officer & Senior VP













CLDX Stock - Frequently Asked Questions

Should I buy or sell Celldex Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLDX shares.
View CLDX analyst ratings
or view top-rated stocks.

What is Celldex Therapeutics' stock price forecast for 2023?

3 brokerages have issued 1 year price targets for Celldex Therapeutics' stock. Their CLDX share price forecasts range from $63.00 to $73.00. On average, they predict the company's share price to reach $66.67 in the next twelve months. This suggests a possible upside of 82.3% from the stock's current price.
View analysts price targets for CLDX
or view top-rated stocks among Wall Street analysts.

How have CLDX shares performed in 2023?

Celldex Therapeutics' stock was trading at $44.57 at the beginning of the year. Since then, CLDX shares have decreased by 18.0% and is now trading at $36.56.
View the best growth stocks for 2023 here
.

When is Celldex Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CLDX earnings forecast
.

How were Celldex Therapeutics' earnings last quarter?

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.09. The biopharmaceutical company had revenue of $0.15 million for the quarter, compared to analysts' expectations of $1.70 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 28.90% and a negative net margin of 4,765.59%.

When did Celldex Therapeutics' stock split?

Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Celldex Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).

What is Celldex Therapeutics' stock symbol?

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Who are Celldex Therapeutics' major shareholders?

Celldex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (3.30%), Geode Capital Management LLC (1.88%), Price T Rowe Associates Inc. MD (1.77%), Marshall Wace LLP (1.42%), Eversept Partners LP (1.19%) and Fred Alger Management LLC (1.11%). Insiders that own company stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends
.

How do I buy shares of Celldex Therapeutics?

Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Celldex Therapeutics' stock price today?

One share of CLDX stock can currently be purchased for approximately $36.56.

How much money does Celldex Therapeutics make?

Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.73 billion and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-112,320,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis.

How many employees does Celldex Therapeutics have?

The company employs 132 workers across the globe.

How can I contact Celldex Therapeutics?

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 454-7120, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911.

This page (NASDAQ:CLDX) was last updated on 3/26/2023 by MarketBeat.com Staff